Stock MLYS MINERALYS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Mineralys Therapeutics, Inc.

Equities

MLYS

US6031701013

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-21 EDT 		5-day change 1st Jan Change
12.04 USD +2.82% Intraday chart for Mineralys Therapeutics, Inc. -4.29% +40.00%
06-20 Mineralys Therapeutics Insider Sold Shares Worth $592,022, According to a Recent SEC Filing MT
06-14 Mineralys Therapeutics, Inc. Announces Changes to its Board CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Mineralys Therapeutics Insider Sold Shares Worth $592,022, According to a Recent SEC Filing
Mineralys Therapeutics, Inc. Announces Changes to its Board
Mineralys Therapeutics Insider Sold Shares Worth $1,252,718, According to a Recent SEC Filing
Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Mineralys Therapeutics, Inc. Announces Alexander Asam Informs That His Decision Not to Stand for Re-Election to the Board
Mineralys Therapeutics Files Mixed-Securities Shelf Registration
Mineralys Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mineralys Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Sector Update: Health Care Stocks Ease in Late Afternoon
Sector Update: Health Care
Mineralys Therapeutics Secures $120 Million Financing Through Private Placement; Shares Rise
Mineralys Therapeutics, Inc. Appoints Minji Kim as Chief Business Officer
Mineralys Therapeutics Reports Dosing of First Subject in Second Lorundrostat Trial in Hypertension
Mineralys Therapeutics, Inc. Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
Mineralys Therapeutics, Inc Presents Data from the Target-HTN Phase 2 Trial That Further Defines an Endotype-Specific Targeted Approach for Treating Uncontrolled or Resistant Hypertension with Lorundrostat
Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Mineralys Therapeutics, Inc. Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
HBM confirme sa perte nette au premier semestre 2022/23
HBM Healthcare anticipe une perte semestrielle de 70 millions
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MLYS Stock
  4. News Mineralys Therapeutics, Inc.
  5. Other languages